Prestige Consumer Healthcare price to free cash flow PBH

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 9.6×
10-year median: 12.1×
Against its 10-year history: 19th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.4× to 19.3×
Peer median: 9.6×

Prestige Consumer Healthcare's price to free cash flow is 9.6× as of Oct 23, 2026.

That is below its ten-year median of 12.1×, lower than on 81% of days in the last ten years.

Over that time it ranged from 7.4× in Oct 2020 to 19.3× in Jun 2017.

The median for 10 large drugmakers of a similar size is 9.6×.

Price to free cash flow over time

median 12.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.6×	9.0×	12.4×
2025	11.8×	11.1×	18.1×
2024	15.2×	13.3×	16.5×
2023	14.1×	12.8×	15.8×
2022	13.1×	10.3×	13.5×
2021	13.6×	8.4×	14.4×
2020	7.9×	7.4×	11.6×
2019	11.0×	7.7×	11.0×
2018	8.6×	8.4×	16.2×
2017	15.7×	14.4×	19.3×
2016	15.3×	13.4×	17.2×
2015	14.8×	13.5×	17.7×
2014	16.5×	11.3×	16.8×
2013	14.8×	10.9×	14.8×
2012	11.1×	10.2×	16.2×

Against its peers

Companies in Drug Manufacturers - General nearest Prestige Consumer Healthcare's size, closest first, today.

Company	Price to free cash flow
PBHPrestige Consumer Healthcare	9.6×
HRMYHarmony Biosciences	n/m
NRIXNurix Therapeutics	7.5×
ANIPANI Pharmaceuticals	9.6×
PAHCPhibro Animal Health	160×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	8.1×
OGNOrganon	6.4×
LQDALiquidia	25.3×
ARQTArcutis Biotherapeutics	100×
INDVIndivior Pharmaceuticals	n/m
Peer median	9.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Prestige Consumer Healthcare

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.